This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

Risperidone Augmentation of Paroxetine in a Case of Severe, Treatment-Refractory Obsessive-Compulsive Disorder Without Comorbid Psychopathology

Ofer Agid and Bernard Lerer

Published: January 31, 1999

Article Abstract

Letter to the Editor

Sir: Risperidone is an atypical antipsychotic drug distinguished from conventional neuroleptics by its antagonism of serotonin receptors of the 5-HT2A and 5-HT7 subtypes while having a similar affinity for dopamine D2 receptors. The novel pharmacologic profile of risperidone suggests the possibility of other therapeutic applications, particularly in disorders putatively associated with abnormal central serotonergic function. Obsessive-compulsive disorder (OCD) is such a disorder, and recent reports suggest that risperidone may be an effective adjunct to treatment of OCD with selective serotonin reuptake inhibitors (SSRIs).

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 60

Quick Links: